Korea University Research and Business Foundation

Jae Sang Hong

Do Hoon Lee

Young Sik Lee

Jong Hoon Kim

Min Seok Choi

Yu Jin Jang

The present disclosure relates to a composition for preventing or treating fibrosis including an inhibitor of cyclin-dependent kinase 17 (CDK17) expression or activity. According to the present disclosure, the inhibitor of CDK17 expression or activity significantly reduces collagen production and cell activity and viability in activated hepatic stellate cells (liver fibrosis cell model), renal tubular epithelial cells (renal fibrosis cell model) in which fibrosis is induced by TGF-β treatment, and alveolar epithelial cells (lung fibrosis cell model) in which fibrosis is induced by TGF-β treatment, indicating that the composition of the present disclosure has an excellent effect in preventing or treating fibrosis.

Composition for preventing or treating fibrosis including an inhibitor of CDK17 expression or activity

The present invention relates to a composition or cell therapeutic agent for preventing or treating liver fibrosis, containing an exosome or exosome-derived ribonucleic acid. The exosome or ribonucleic acid derived therefrom, of the present invention, has effects of inhibiting activities of hepatic stellate cells and Kupffer cells and reducing the expression of &#x3b1;-SMA and inhibits the progression of liver fibrosis by inhibiting the deposition of collagen, thereby being effectively usable as a cell therapeutic agent for the prevention or treatment of liver fibrosis.

Growing community of inventors

Seoul, South Korea

Jae Sang Hong